Прогностическая и предиктивная значимость маркера Ki67 при раке молочной железы

Автор: Тележникова И.М., Сетдикова Г.Р., Еремеева Е.Р., Тюрина В.М., Жукова Л.Г.

Журнал: Злокачественные опухоли @malignanttumors

Статья в выпуске: 3S1 т.12, 2022 года.

Бесплатный доступ

Статья посвящена проблеме аналитической и клинической валидности иммуногистохимического маркера пролиферации — белка Ki67 — при раке молочной железы (РМЖ). В статье проведён анализ русско- и англоязычных публикаций из баз данных PubMed, Google Scholar, ClinicalTrials. gov, eLibrary, Cyberleninka. В ней кратко рассматриваются проблемы стандартизации исследования данного маркера и факторы, способствующие разногласиям между лабораториями. Также в статье обсуждается место иммуногистохимии в современной классификации опухолей молочной железы. Кроме того, освещаются проблемы, связанные с определением оптимального пограничного значения для разграничения люминальных подтипов РМЖ. Приводятся основные результаты исследований по прогностической и предиктивной значимости Ki67 у пациентов с ER + / HER2– РМЖ, включая его значимость для определения показаний к адъювантной химиотерапии и использование динамического изменения Ki67 в качестве критерия ответа на эндокринную неоадъювантную терапию. Кратко обсуждаются иные подходы к оценке прогноза при РМЖ, в частности, современные генетические тесты и онлайн-платформы оценки риска. В статье обобщаются наиболее актуальные рекомендации по использованию Ki67 при РМЖ, включая положения Сент-Галленского консенсуса от 2021 г., обновленные клинические рекомендации Американского общества клинической онкологии (ASCO) по использованию биомаркеров при РМЖ, а также актуальные рекомендации Международной рабочей группы по интерпретации Ki67 при РМЖ (IKWG) от 2020 года. Обсуждаются современные подходы к исследованию Ki67, включая разработанную IKWG систему визуальной оценки Ki67 по методике Global и вспомогательные инструменты для автоматизированной оценки. Согласно данным литературы, на сегодняшний день Ki67 остается удобным и доступным методом для оценки прогноза при РМЖ, однако при его интерпретации необходимо учитывать ограничения методик оценки. В настоящее время сохраняется необходимость проведения дальнейших исследований для стандартизации, определения оптимального порогового уровня Ki67 и валидации автоматизированных систем его подсчета, которые потенциально могут способствовать улучшению согласованности оценки и интерпретации результатов исследования данного маркера.

Еще

Рак молочной железы, молекулярные маркеры, иммуногистохимия, Ki67

Короткий адрес: https://sciup.org/140295813

IDR: 140295813   |   DOI: 10.18027/2224-5057-2022-12-3s1-27-38

Список литературы Прогностическая и предиктивная значимость маркера Ki67 при раке молочной железы

  • Злокачественные новообразования в России в 2020 году (заболеваемость и смертность) / МНИОИ им. П. А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России ; под ред. А. Д. Каприна, В. В. Старинского, А. О. Шахзадовой. М., 2021. 252 с.
  • Houghton S. C., Hankinson SE. Cancer Progress and Priorities : Breast Cancer // Cancer Epidemiol Biomarkers Prev. 2021. Vol. 30, № 5. P. 822-844.
  • Global Burden of Disease 2019 Cancer Collaboration. Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life Years for 29 Cancer Groups From 2010 to 2019 : A Systematic Analysis for the Global Burden of Disease Study 2019 // JAMA Oncol. 2022. Vol. 8, № 3. P. 420-444.
  • Yeo S. K., Guan J. L. Breast Cancer : Multiple Subtypes within a Tumor? // Trends Cancer. 2017. Vol. 3, № 11. Р. 753-60.
  • Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast cancer // Lancet. 2021. Vol. 397, № 10286. Р. 1750-69.
  • Tsang J. Y. S., Tse G. M. Molecular Classification of Breast Cancer // Adv Anat Pathol. 2020. Vol. 27, № 1. P. 27-35.
  • Zubair M., Wang S., Ali N. Advanced Approaches to Breast Cancer Classification and Diagnosis // Front Pharmacol. 2021. Vol. 11. Р. 632079.
  • Schonk D. M., Kuijpers H. J., van Drunen E., van Dalen C. H., Geurts van Kessel A. H., Verheijen R., Ramaekers F. C. Assignment of the gene (s) involved in the expression of the proliferation-related Ki-67 antigen to human chromosome 10 // Hum Genet. 1989. Vol. 83, № 3. P. 297-9.
  • Gutschner T., Diederichs S. The hallmarks of cancer : a long non-coding RNA point of view // RNA Biol. 2012. Vol. 9, № 6. Р. 703-19.
  • Davey M. G., Hynes S. O., Kerin M. J., Miller N., Lowery A. J. Ki67 as a Prognostic Biomarker in Invasive Breast Cancer // Cancers (Basel). 2021. Vol. 13, № 17. Р. 4455.
  • Dowsett M., Nielsen T. O., A’Hern R., Bartlett J., Coombes R. C., Cuzick J. et al. Assessment of Ki67 in breast cancer : recommendations from the International Ki67 in Breast Cancer working group // J Natl Cancer Inst. 2011. Vol. 103, № 22. Р. 1656-64.
  • Arima N., Nishimura R., Osako T., Nishiyama Y., Fujisue M., Okumura Y. et al. The importance of tissue handling of surgically removed breast cancer for an accurate assessment of the Ki-67 index // J Clin Pathol. 2016. Vol. 69, № 3. Р. 255-9.
  • Nielsen T. O., Leung S. C. Y., Rimm D. L., Dodson A., Acs B., Badve S. et al. Assessment of Ki67 in Breast Cancer : Updated Recommendations From the International Ki67 in Breast Cancer Working Group // J Natl Cancer Inst. 2021. Vol. 113, № 7. P. 808-19.
  • Romero Q., Bendahl P. O., Fernö M., Grabau D., Borgquist S. A novel model for Ki67 assessment in breast cancer // Diagn Pathol. 2014. Vol. 9. P. 118.
  • Shui R., Yu B., Bi R., Yang F., Yang W. An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer // PLoS One. 2015. Vol. 10, № 5. P. e0125131.
  • Meermira D., Swain M., Gowrishankar S. Study of Ki-67 index in the molecular subtypes of breast cancer : Inter-observer variability and automated scoring // Indian J Cancer. 2020. Vol. 57, № 3. Р. 289-95.
  • Focke C. M., Bürger H., van Diest P. J., Finsterbusch K., Gläser D., Korsching E., Decker T. ; German Breast Screening Pathology Initiative. Interlaboratory variability of Ki67 staining in breast cancer // Eur J Cancer. 2017. Vol. 84. P. 219-27.
  • College of American Pathologists. Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. URL : https://documents.cap.org / protocols / Breast. Bmk_1.4.1.0. REL_CAPCP. pdf (дата обращения : 20.08.2022).
  • Tan P. H., Ellis I., Allison K., Brogi E., Fox S. B., Lakhani S. et al. The 2019 World Health Organization classification of tumours of the breast // Histopathology. 2020. Vol. 77, № 2. Р. 181-5.
  • Lebeau A., Denkert C. Aktualisierte WHO-Klassifikation der Tumoren der Mamma : Die wichtigsten Änderungen [Updated WHO classification of tumors of the breast : the most important changes] // Pathologe. 2021. Vol. 42, № 3. Р. 270-80.
  • Goldhirsch A., Ingle J. N., Gelber R. D., Coates A. S., Thürlimann B., Senn H. J. ; Panel members. Thresholds for therapies : highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 // Ann Oncol. 2009. Vol. 20, № 8. Р. 1319-29.
  • Goldhirsch A., Wood W. C., Coates A. S., Gelber R. D., Thürlimann B., Senn H. J. ; Panel members. Strategies for subtypes--dealing with the diversity of breast cancer : highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 // Ann Oncol. 2011. Vol. 22, № 8. Р. 1736-47.
  • Goldhirsch A., Winer E. P., Coates A. S., Gelber R. D., PiccartGebhart M., Thürlimann B., Senn H. J. ; Panel members. Personalizing the treatment of women with early breast cancer : highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 // Ann Oncol. 2013. Vol. 24, № 9. Р. 2206-23.
  • Maisonneuve P., Disalvatore D., Rotmensz N., Curigliano G., Colleoni M., Dellapasqua S. et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes // Breast Cancer Res. 2014. Vol. 16, № 3. Р. R65.
  • Kurozumi S., Matsumoto H., Hayashi Y., Tozuka K., Inoue K., Horiguchi J. et al. Power of PgR expression as a prognostic factor for ER-positive / HER2-negative breast cancer patients at intermediate risk classified by the Ki67 labeling index // BMC Cancer. 2017. Vol. 17, № 1. Р. 354.
  • Coates A. S., Winer E. P., Goldhirsch A., Gelber R. D., Gnant M., Piccart-Gebhart M. et al. Tailoring therapies-improving the management of early breast cancer : St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 // Ann Oncol. 2015. Vol. 26, № 8. P. 1533-46.
  • Hida A. I., Oshiro Y., Inoue H., Kawaguchi H., Yamashita N., Moriya T. Visual assessment of Ki67 at a glance is an easy method to exclude many luminal-type breast cancers from counting 1000 cells // Breast Cancer. 2015. Vol. 22, № 2. Р. 129-34.
  • Raap M., Ließem S., Rüschoff J., Fisseler-Eckhoff A., Reiner A., Dirnhofer S. et al. Quality assurance trials for Ki67 assessment in pathology // Virchows Arch. 2017. Vol. 471, № 4. Р. 501-508.
  • Leung S. C. Y., Nielsen T. O., Zabaglo L. A., Arun I., Badve S. S., Bane A. L. et al. Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections : an international multicentre collaboration // Histopathology. 2019. Vol. 75, № 2. Р. 225-35.
  • Kadivar M., Aram F. Assessment of Ki67 in Breast Cancer : A Comparison Between the Eye-10 Method, Stepwise Counting Strategy, and International System of Ki67 Evaluation // Iran J Pathol. 2020. Vol. 15, № 1. Р. 13-18.
  • van den Berg E. J., Duarte R., Dickens C., Joffe M., Mohanlal R. Ki67 Immunohistochemistry Quantification in Breast Carcinoma : A Comparison of Visual Estimation, Counting, and ImmunoRatio // Appl Immunohistochem Mol Morphol. 2021. Vol. 29, № 2. Р. 105-11.
  • Muftah A. A., Aleskandarany M. A., Al-Kaabi M. M., Sonbul S. N., Diez-Rodriguez M., Nolan C. C. et al. Ki67 expression in invasive breast cancer : the use of tissue microarrays compared with whole tissue sections // Breast Cancer Res Treat. 2017. Vol. 164, № 2. Р. 341-8.
  • Lombardi A., Lazzeroni R., Bersigotti L., Vitale V., Amanti C. The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer : A Monoinstitutional Analysis with Long-Term Follow-Up // Breast Cancer (Dove Med Press). 2021 Vol. 13. P. 213-7.
  • Maranta A. F., Broder S., Fritzsche C., Knauer M., Thürlimann B., Jochum W., Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki67 index distribution and its robustness is essential for decision-making in early breast cancer // Breast. 2020. Vol. 51. P. 120-6.
  • Клинические рекомендации : Рак молочной железы. 2021. URL : https://oncology-association.ru/wp-content/uploads/2021/02/rak-molochnoj-zhelezy-2021.pdf (дата обращения : 20.08.2022).
  • Petrelli F., Viale G., Cabiddu M., Barni S. Prognostic value of different cut-off levels of Ki-67 in breast cancer : a systematic review and meta-analysis of 64,196 patients // Breast Cancer Res Treat. 2015. Vol. 153, № 3. Р. 477-91.
  • Tashima R., Nishimura R., Osako T., Nishiyama Y., Okumura Y., Nakano M. et al. Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer : A Retrospective Study // PLoS One. 2015. Vol. 10, № 7. Р. e0119565.
  • Cho U., Kim H. E., Oh W. J., Yeo M. K., Song B. J., Lee A. The Long-term Prognostic Performance of Ki-67 in Primary Operable Breast Cancer and Evaluation of Its Optimal Cutoff Value // Appl Immunohistochem Mol Morphol. 2016. Vol. 24, № 3. Р. 159-66.
  • Ohara M., Matsuura K., Akimoto E., Noma M., https://doi.org/M., Nishizaka T. et al. Prognostic value of Ki67 and p53 in patients with estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer : Validation of the cut-off value of the Ki67 labeling index as a predictive factor // Mol Clin Oncol. 2016. Vol. 4, № 4. Р. 648-54.
  • Fasching P. A., Gass P., Häberle L., Volz B., Hein A., Hack C. C. et al. Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer // Breast Cancer Res Treat. 2019. Vol. 175, № 3. Р. 617-25.
  • Viale G., Hanlon Newell A. E., Walker E., Harlow G., Bai I., Russo L. et al. Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes // Breast Cancer Res Treat. 2019. Vol. 178, № 2. Р. 451-8.
  • Gallardo A., Garcia-Valdecasas B., Murata P., Teran R., Lopez L., Barnadas A., Lerma E. Inverse relationship between Ki67 and survival in early luminal breast cancer : confirmation in a multivariate analysis // Breast Cancer Res Treat. 2018. Vol. 167, № 1. Р. 31-7.
  • Varga Z., Li Q., Jochum W., Perriard U., Rau T., Tille J. C. et al. Ki-67 assessment in early breast cancer : SAKK28 / 12 validation study on the IBCSG VIII and IBCSG IX cohort // Sci Rep. 2019. Vol. 9, № 1. Р. 13534.
  • Denkert C., Budczies J., Regan M. M., Loibl S., Dell’Orto P., von Minckwitz G. et al. Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial : systematic modulation of interobserver variance in a comprehensive in silico ring trial // Breast Cancer Res Treat. 2019. Vol. 176, № 3. Р. 557-68.
  • Yang Z. J., Liu Y. X., Huang Y., Chen Z. J., Zhang H. Z., Yu Y. et al. The regrouping of Luminal B (HER2 negative), a better discriminator of outcome and recurrence score // Cancer Med. 2022. https://doi.org/10.1002/cam4.5089.[Epub ahead of print.].
  • Criscitiello C., Disalvatore D., De Laurentiis M., Gelao L., Fumagalli L., Locatelli M. et al. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in luminal B HER2 negative and node-positive breast cancer // Breast. 2014. Vol. 23, № 1. Р. 69-75.
  • Sonnenblick A., Francis P. A., Azim H. A. Jr., de Azambuja E., Nordenskjöld B., Gutiérez J. et al. Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer // Eur J Cancer. 2015. Vol. 51, № 12. Р. 1481-9.
  • Li L., Han D., Wang X., Wang Q., Tian J., Yao J. et al. Prognostic values of Ki-67 in neoadjuvant setting for breast cancer : a systematic review and meta-analysis // Future Oncol. 2017. Vol. 13, № 11. Р. 1021-34.
  • Chen X., He C., Han D., Zhou M., Wang Q., Tian J. et al. The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer : a systematic review and meta-analysis // Future Oncol. 2017. Vol. 13, № 9. Р. 843-57.
  • Ács B., Zámbó V., Vízkeleti L., Szász A. M., Madaras L., Szentmártoni G. et al. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy // Diagn Pathol. 2017. Vol. 12, № 1. Р. 20.
  • Chen R., Ye Y., Yang C., Peng Y., Zong B., Qu F. et al. Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification : a retrospective study of 1010 patients // Breast Cancer Res Treat. 2018. Vol. 170, № 1. Р. 35-43.
  • Boughey J. C., Hoskin T. L., Goetz M. P. Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer : Effects of Age and Tumor Ki67 // Ann Surg Oncol. 2022. Vol. 29, № 9. Р. 5747-56.
  • Choi H. J., Lee J. H., Jung C. S., Lee J. E., Jung Y. J., Lee S. et al. Factors Affecting Pathologic Complete Remission in Patients with Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy // Oncology. 2022. https://doi.org/10.1159/000526155. [Epub ahead of print].
  • Holanek M., Selingerova I., Fabian P., Coufal O., Zapletal O., Petrakova K. et al. Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy // Diagnostics (Basel). 2022. Vol. 12, № 7. Р. 1740.
  • Kim J. Y., Oh J. M., Lee S. K., Yu J., Lee J. E., Kim S. W. et al. Improved Prediction of Survival Outcomes Using Residual Cancer Burden in Combination With Ki-67 in Breast Cancer Patients Underwent Neoadjuvant Chemotherapy // Front Oncol. 2022. Vol. 12. P. 903372.
  • Matsubara N., Mukai H., Masumoto M., Sasaki M., Naito Y., Fujii S, Wada N. Survival outcome and reduction rate of Ki-67 between pre- and post-neoadjuvant chemotherapy in breast cancer patients with non-pCR // Breast Cancer Res Treat. 2014. Vol. 147, № 1. Р. 95-102.
  • Montagna E., Bagnardi V., Viale G., Rotmensz N., Sporchia A., Cancello G. et al. Changes in PgR and Ki-67 in residual tumour and outcome of breast cancer patients treated with neoadjuvant chemotherapy // Ann Oncol. 2015. Vol. 26, № 2. Р. 307-13.
  • Rossi L., Verrico M., Tomao S., Ricci F., Fontana A., Spinelli G. P. et al. Expression of ER, PgR, HER-2, and Ki-67 in core biopsies and in definitive histological specimens in patients with local- ly advanced breast cancer treated with neoadjuvant chemotherapy // Cancer Chemother Pharmacol. 2020. Vol. 85, № 1. Р. 105-11.
  • Pistelli M., Merloni F., Crocetti S., Scortichini L., Tassone L., Cantini L. et al. Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy : A Single Institution Experience // J Oncol. 2021. Vol. 2021. P. 5548252.
  • von Minckwitz G., Schmitt W. D., Loibl S., Müller B. M., Blohmer J. U., Sinn B. V. et al. Ki67 measured after neoadjuvant chemotherapy for primary breast cancer // Clin Cancer Res. 2013. Vol. 19, № 16. Р. 4521-31.
  • Ding Y., Ding K., Qian H., Yu X., Zou D., Yang H. et al. Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer // PLoS One. 2020. Vol. 15, № 4. Р. e0231895.
  • Tan S., Fu X., Xu S., Qiu P., Lv Z., Xu Y., Zhang Q. Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy // Pathol Oncol Res. 2021. Vol. 27. P. 1609972.
  • Dowsett M., Smith I. E., Ebbs S. R., Dixon J. M., Skene A., Griffith C. et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival // Clin Cancer Res. 2005. Vol. 11, № 2Pt 2. P 951s-8s.
  • Ellis M. J., Miller W. R., Tao Y., Evans D. B., Chaudri Ross H. A., Miki Y. et al. Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial // Breast Cancer Res Treat. 2009. Vol. 116, № 2. Р. 371-8.
  • Ellis M. J., Suman V. J., Hoog J., Lin L., Snider J., Prat A. et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer : clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031 // J Clin Oncol. 2011. Vol. 29, № 17. Р. 2342-9.
  • Zhang A., Wang X., Fan C., Mao X. The Role of Ki67 in Evaluating Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer // Front Endocrinol (Lausanne). 2021. Vol. 12. P. 87244.
  • Ellis M. J., Tao Y., Luo J., A’Hern R., Evans D. B., Bhatnagar A. S. et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics // J Natl Cancer Inst. 2008. Vol. 100, № 19. Р. 1380-8.
  • Lerebours F., Pulido M., Fourme E., Debled M., Becette V., Bonnefoi H. et al. Predictive factors of 5-year relapse-free survival in HR + / HER2- breast cancer patients treated with neoadjuvant endocrine therapy : pooled analysis of two phase 2 trials // Br J Cancer. 2020. Vol. 122, № 6. Р. 759-65.
  • Smith I., Robertson J., Kilburn L., Wilcox M., Evans A., Holcombe C. et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC) : an open-label, multicentre, parallel-group, randomised, phase 3 trial // Lancet Oncol. 2020. Vol. 21, № 11. Р. 1443-54.
  • Ellis M. J., Suman V. J., Hoog J., Goncalves R., Sanati S., Creighton C. J. et al. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer : Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance) // J Clin Oncol. 2017. Vol. 35, № 10. Р. 1061-69.
  • Johnston S. R. D., Harbeck N., Hegg R., Toi M., Martin M., Shao Z. M., Zhang Q. Y. et al. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR +, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE) // J Clin Oncol. 2020. Vol. 38, № 34. Р. 3987-98.
  • Alternate Approaches for Clinical Stage II or III Estrogen Receptor Positive Breast Cancer Neoadjuvant Treatment (ALTERNATE) in Postmenopausal Women : A Phase III Study. URL : https://clinicaltrials.gov/ct2/show/NCT01953588 (дата обращения : 20.08.2022).
  • Burstein H. J., Curigliano G., Thürlimann B., Weber W. P., Poortmans P., Regan M. M. et al. Customizing local and systemic therapies for women with early breast cancer : the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 // Ann Oncol. 2021. Vol. 32, № 10. Р. 1216-35.
  • Thomssen C., Balic M., Harbeck N., Gnant M. St. Gallen / Vienna 2021 : A Brief Summary of the Consensus Discussion on Customizing Therapies for Women with Early Breast Cancer // Breast Care (Basel). 2021. Vol. 16, № 2. Р. 135-43.
  • Hacking S. M., Yakirevich E., Wang Y. From Immunohistochemistry to New Digital Ecosystems : A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine // Cancers (Basel). 2022. Vol. 14, № 14. Р. 3469.
  • Syed Y. Y. Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer // Mol Diagn Ther. 2020. Vol. 24, № 5. Р. 621-32.
  • Sparano J. A., Gray R. J., Makower D. F., Pritchard K. I., Albain K. S., Hayes D. F. et al. Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer // N Engl J Med. 2018. Vol. 379, № 2. Р. 111-21.
  • Nitz U., Gluz O., Christgen M., Kates R. E., Clemens M., Malter W. et al. Reducing chemotherapy use in clinically highrisk, genomically low-risk pN0 and pN1 early breast cancer patients : five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial // Breast Cancer Res Treat. 2017. Vol. 165, № 3. Р. 573-83.
  • Andre F., Ismaila N., Allison K. H., Barlow W. E., Collyar D. E., Damodaran S. et al. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer : ASCO Guideline Update // J Clin Oncol. 2022. Vol. 40, № 16. Р. 1816-37.
  • Brandão M., Pondé N., Piccart-Gebhart M. Mammaprint™: a comprehensive review // Future Oncol. 2019. Vol. 15, № 2. Р. 207-24.
  • Drukker C. A., Bueno-de-Mesquita J. M., Retèl V. P., van Harten W. H., van Tinteren H., Wesseling J. et al. A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study // Int J Cancer. 2013. Vol. 133, № 4. Р. 929-36.
  • Cardoso F., van’t Veer L. J., Bogaerts J., Slaets L., Viale G., Delaloge S. et al. 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer // N Engl J Med. 2016. Vol. 375, № 8. Р. 717-29.
  • Wallden B., Storhoff J., Nielsen T., Dowidar N., Schaper C., Ferree S. et al. Development and verification of the PAM50-based Prosigna breast cancer gene signature assay // BMC Med Genomics. 2015. Vol. 8. P. 54.
  • Puppe J., Seifert T., Eichler C., Pilch H., Mallmann P., Malter W. Genomic Signatures in Luminal Breast Cancer // Breast Care (Basel). 2020. Vol. 15, № 4. Р. 355-65.
  • Gnant M., Filipits M., Greil R., Stoeger H., Rudas M., Bago-Horvath Z. et al. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk : using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone // Ann Oncol. 2014. Vol. 25, № 2. Р. 339-45.
  • Ohnstad H. O., Borgen E., Falk R. S., Lien T. G., Aaserud M., Sveli M. A. T. et al. Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up // Breast Cancer Res. 2017. Vol. 19, № 1. Р. 120.
  • Глобал Индекс РМЖ (Global Index BC). URL: http://globalindexbc.ru / (дата обращения 20.08.2022).
  • Hall P. S., Smith A., Hulme C., Vargas-Palacios A., Makris A., Hughes-Davies L. et al. Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer : The OPTIMA Prelim Trial // Value Health. 2017. Vol. 20, № 10. Р. 1311-18.
  • Kjällquist U., Acs B., Margolin S., Karlsson E., Kessler L. E., Garcia Hernandez S. et al. Real World Evaluation of the Prosigna / PAM50 Test in a Node-Negative Postmenopausal Swedish Population : A Multicenter Study // Cancers (Basel). 2022. Vol. 14, № 11. Р. 2615.
  • Markopoulos C., van de Velde C., Zarca D., Ozmen V., Masetti R. Clinical evidence supporting genomic tests in early breast cancer : Do all genomic tests provide the same information? // Eur J Surg Oncol. 2017. Vol. 43, № 5. Р. 909-920.
  • Bartlett J. M., Bayani J., Marshall A., Dunn J. A., Campbell A. et al. Comparing Breast Cancer Multiparameter Tests in the OP- TIMA Prelim Trial : No Test Is More Equal Than the Others // J Natl Cancer Inst. 2016. Vol. 108, № 9. Р. djw050.
  • Buus R., Sestak I., Kronenwett R., Ferree S., Schnabel C. A., Baehner F. L. et al. Molecular Drivers of Oncotype DX, Prosigna, EndoPredict, and the Breast Cancer Index : A TransATAC Study // J Clin Oncol. 2021. Vol. 39, № 2. Р. 126-135.
  • Fernandez-Martinez A., Pascual T., Perrone G., Morales S., de la Haba J., González-Rivera M. et al. Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer // Oncotarget. 2017. Vol. 8, № 13. Р. 21930-7.
  • Noske A., Anders S. I., Ettl J., Hapfelmeier A., Steiger K. et al. Risk stratification in luminal-type breast cancer : Comparison of Ki-67 with EndoPredict test results // Breast. 2020. Vol. 49. P. 101-107.
  • Amezcua-Gálvez J. E., Lopez-Garcia C. A., Villarreal-Garza C., Lopez-Rivera V., Canavati-Marcos M., Santuario-Facio S. et al. Concordance between Ki-67 index in invasive breast cancer and molecular signatures : EndoPredict and MammaPrint // Mol Clin Oncol. 2022. Vol. 17, № 3. Р. 132.
  • University of Tennessee Medical Center. Updated Breast Cancer Nomograms : Prediction for a Low-risk and a High-risk Oncotype DX Recurrence Score. URL:https://utgsm.shinyapps.io/OncotypeDXCalculator (дата обращения : 20.08.2022).
  • Predict Breast Cancer. URL : https://breast.predict.nhs.uk / (дата обращения 20.08.2022).
  • Slembrouck L., Vanden Bempt I., Wildiers H., Smeets A., Van Rompuy A. S., Van Ongeval C. et al. Concordance between results of inexpensive statistical models and multigene signatures in patients with ER + / HER2- early breast cancer // Mod Pathol. 2021. Vol. 34, № 7. Р. 1297-1309.
  • Yamaguchi K., Matsunuma R., Hayami R., Tsuneizumi M. Comparison of the Modified Immunohistochemical Marker Score and 21-Gene Recurrence Score Assay in Patients with Estrogen Receptor-Positive Breast Cancer // Oncology. 2022. Vol. 100, № 3. Р. 155-62.
  • Wolff A. C., Hammond M. E. H., Allison K. H., Harvey B. E., Mangu P. B., Bartlett J. M. S. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update // J Clin Oncol. 2018. Vol. 36, № 20. Р. 2105-22.
  • International Ki67 in Breast Cancer Working Group. URL: https://www.ki67inbreastcancerwg.org / (дата обращения : 20.08.2022).
  • Polley M. Y., Leung S. C., Gao D., Mastropasqua M. G., Zabaglo L. A., Bartlett J. M. et al. An international study to increase concordance in Ki67 scoring // Mod Pathol. 2015. Vol. 28, № 6. Р. 778-86.
  • Leung S. C. Y., Nielsen T. O., Zabaglo L., Arun I., Badve S. S., Bane A. L. et al. Analytical validation of a standardized scoring protocol for Ki67 : phase 3 of an international multicenter collaboration // NPJ Breast Cancer. 2016. Vol. 2. P. 16014.
  • Тележникова И. М., Жукова Л. Г., Хатькова Е. И., Шурыгина Е. И., Сетдикова Г. Р. Применение методики визуальной интерпретации Global для оценки Ki67 при раке молочной железы // Вопросы онкологии. 2022. Т. 68, № S3. С. 124-5.
  • Boyaci C., Sun W., Robertson S., Acs B., Hartman J. Independent Clinical Validation of the Automated Ki67 Scoring Guideline from the International Ki67 in Breast Cancer Working Group // Biomolecules. 2021. Vol. 11, № 11. Р. 1612.
  • Negahbani F., Sabzi R., Pakniyat Jahromi B., Firouzabadi D., Movahedi F., Kohandel Shirazi M. et al. PathoNet introduced as a deep neural network backend for evaluation of Ki-67 and tumor-infiltrating lymphocytes in breast cancer // Sci Rep. 2021. Vol. 11, № 1. Р. 8489.
  • Acs B., Pelekanou V., Bai Y., Martinez-Morilla S., Toki M., Leung S. C. Y. et al. Ki67 reproducibility using digital image analysis : an inter-platform and inter-operator study // Lab Invest. 2019. Vol. 99, № 1. Р. 107-117.
  • Rimm D. L., Leung S. C. Y., McShane L. M., Bai Y., Bane A. L., Bartlett J. M. S. et al. An international multicenter study to evaluate reproducibility of automated scoring for assessment of Ki67 in breast cancer // Mod Pathol. 2019. Vol. 32, № 1. Р. 59-69.
Еще
Статья научная